New Incentives Needed to Develop Antibiotics to Fight Superbugs

JFIF;CREATOR: gd-jpeg v1.0 (using IJG JPEG v62), quality = 80 C   %# , #&')*)-0-(0%()(C   ((((((((((((((((((((((((((((((((((((((((((((((((((( " }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?KIAAEb ( ( (4PIKE%(A%-%-RwHii(QEQEQEJ(QE'-%P(AHaIZJ(:QEz)~uP) RR(AJ(4 Ο#¬6!}2. B$Wl4l@aArBkem11\-{0m?K=i QVvsi"Lלkړj7.~\ w=Č|v?MtRir!Q[嶹 !k^o5U25qV=]Z92Z6$Òwxtۇ^iHOc] inMTgi7پPRg`އk7rB]_5xwgx~ fuV˕aVwƽ;tޝZ|zl8֘͌>m%fӖŮe6A?(nUu1\Rz#*moI3Y,S$\?S[ 0b_cH^LF'ҝ?g-(&s5$V3ָ:ͶԜ w"**@恵xpݳ]n*t8^at.׀׵vV7Bh$YݵSU!-ujtۋ.YO4c@}1\M5*U/̴8jW2-GxQX\N01>wVKa2$HY hMbg.Uyi[DeIq4yH4Cڃr—85Mm w`yZά*'QޝVBg%g#ZןW.&%3*dY0! aY65*TҗC*I9ف6xohcź >~znp޹;/>]9te̊PeH=zuSm&Jjy5CS8=ЎƥN8i1ҷ;v=k ,q[Z$ҔPՅoy8q[h&/rpq&5 \di\K"T5Q*M$O2?ikv+#B(A(PQEQE ))hBQKEZ()i(-%QE0 PRQH)hQE (aEt 4 JQPQA4Qފ(4PEPA 1EJ=4Қ@%RQJ(E9G4Rƹ4.*l5J̴$q[qVni'ztQ7:W1ֽ>IJ=^6mh{1VH8[ˑֱ5V ƮiZ-yvZ}uƜaMCdz,s"k'ʴa-1\.,7TW=~hD n<# ^2m&IgC,*nUR6,jmRDA!6dmhA3bzS$_3N$ԕR4Gı'>gEhMM. Ǻ@:SVT}kz^[+\H?@zQh.m,ip3s<3ڬL]EWCpq3Ev}k2jv"qWs 9]^e{cwcEi%8WYYܬ5lp9dY%Fy$N;K.T5Cn HRwvRfm^ L\Dv*2 *X3#5GF{ 4~y x=6-NMz5)%z[_[BGp:`KlڲL&,NME* is4*:zP*DnkP9út1']ð~.}&WkѤKWC'Z*JszWEtn@z+{(1GVVcMo嘗1?NSl|yI@4WąQ@Q@Rh(PEPHihaE%-%-%-QEP((@ ERi(ZJZ(QE))i) (% Jhv((4QKHaIK@C-%PREN@QV`L&ǜVSP/Gҷ,v8qZȯ>{!cJܞ3]߆u88\$cf}ͭMTV=%֧r*H)II5[xG}hJOCom\W2ZٜI$9vB 6yU4Cy_CjȡFk4>-ekUPEJ|BH,sk]CgaBoA^k9>ffBm k{ Rur# y j 0H^/6+6 Hz^:4Zgc]jȑ@iQó5Ŋ\1\>`חK56IkON]ɫӊP!`WTԢ\f: vysc`w NּU%MM fM*~WR_>wSQBNU;? +{]J:QCs7Rҟ |/q\tO36$rNJip|t9mk&K(qSz}+}V6kZG$idh|q]7igrw]NJURՖ[uF{$zSlg]G7o=m,Hqa|Q\k٥GM)´jKKēTvOHɧ#jPe! XKf4\ ;2:RnTb#Qp,څŚmSW_Vlu GlVZASr⹝Hژ:mNI,g@ѐs]挫*z-7c2XEW:Cn\5A q\RJaJ8QQڜh[vvQIr-=N,:xp>fZ>k-,p.w(X`+sa߁Z'ϩ'ssQ YxMD$lau!7w/UKe`XEpm+.WJrW0N-v8GnFHyF2y<ӧ8!^1.=*ެ֬beK_-ELLYRx/0#tf].ylg=qTyR=6n#@Nx3c֩Pm#c&I\WYT1k7FPSuKxc\MY^&Xoٜ42n:=bTi G?4qv?+ ;EPE-J(bQފ((((I@ IKI@-%-4EPRъ)RR@RR@Ph)RZ %QHbPzQߚ(KGzJ)Z QH9 @(ƤIi O2IztHlWt !z$tТ3 ޭI໯/1c^SCL}zךӹ,,xر`={ViBz᜘,>x^g hE*톞,FEu񊦌䯅vTRms(ZLIZ#.Z[TlZ#֡kx:U,1V;z09 o *}8*S]ʮS.&PU9?%nmWp84@n3+X\+ *MzWxMയO ߽rv$&!MvJ\*ulnQ\S. ,!Iöw.'(* a ʤR&X-xfݼ.[K՟;ʇJJYa;F@?Z1Cuȶ,heL#޽_D$na6US^k=ߓ+ECM>h3HeX=TkU:R$G>V_'~3^a%ړ!EOAXVrZR9)R_y%ΥuX95gK{hֱGjy1=x~ejo\AK&~9YFعJQq絞d1ݴTzu SBJWL/5kۃjOЦ]+Nd,cA1jx U(N^ٌL`dzgY^|kӮ/RHin jVXwHҥQ98R2I4kNwSӱѤ}*:"b?od|)*jf7'f|IE…Q@QҀQEQEQEQEQ@EPE%-0 PRE!ފZ()h ( ZJ^ԀJ(4Qڊ(RRRRP(@ @4@?Vk8^kӊ!Gq^mkkR6B0xg)bx=ktۆɌ ڵBMR֣;Cǽ&4i!2 Rjs=Fdoƺ%."e z0˒{椐eѦk雱(ݒBKXulrԑFhVx5jٴW I(6v+A{ ׏Ad, ٪$p3VscĴvGZKht*;WQK{2uˤXj]"<5BtZQlʎqZJ.4knAȩ {V]iuf`T͕D|q\WicWQ71ŧ$cnϦ}*TX!Uiɩ~]M}j$&TU+ٖFcSA=테WIlm);%=k5{C1 hweR殶:;SX5ķkRETtOX/d<:0Y-^8r^suB*\jI 8co¸B2It\?Eli~KYLv) cp/\\X nyÞT8Gt:ѯ l*TVt)TJ9qj7c1W{_9`A]_CD(pyZA})cqQ乶zrϞ j]t&Դ-0LsT|'*-'~in$֞JҶyYЩ(Ů祦":tM:5kk4m5N#\2.@8K Ctn(Wdڡr+aa 7ݿJܡJ`1m({mocY[dlpAUu!hW2O /#tf{XmL)AbmIK#Sٕ‡po-ךǐs^ⶰm,M1br}Gak[l4p ]˖:#z5sMXf[ )Qޫ7=Ȯg[M;S ,g!t~'XS~|{fB1٣P5Kh+ie Fen۹Υz$@ϻcZi:6LX+xu- Nz1JR>e6)u)׾'-H031$woƱYm+ XvIC}jG63hOW&/eYNg.YoQ_^|8QE(Q@ EPEQEQEQERPGҊ((((HaEPE(h4EJ(4P0PQKCH{})) SIE-0 QIE -5"k<9ŨZ7N*r#sb(*t(޴o/n([?Xwf=c`֬# Uiglɯ- ?oŷڞ Dkf,ry&>yr1^r1VaOn*$bۥvV0ۧ8=*t!J=*P.[ sZV<}g=Nho] n׋ ךY3q]n0JPwGeedב(4Ҽ[xn7dG?.0}="PwsU]QD%Udr$wUmH?g''5*˞>mqE,xw PyNs#5tu^I'8x@EWvZ wvsyؔscwNXYs >^F{󌁰ƴ8hzFf#ڱm6XrS0 w4KVi ;fX;$#Z:"k&HÑ\jRJEu8pA[۟5,72F@jrjs5W0*4˽C cZ-uͶ@#5Ӽ;}j<+;-'ԯu nV,T(ϰV赒{)㺵[HURZd>3ژ9}E;\wmzwZ}/61ΥKb+[Q@`)QE(((QERREPE((aEQEQKI@QH(RRPP(J)i Rzސ yRQڊc (S6RH 86*:pd1Fj NưW,[ZPG^>EiAJ圏F aAW^ }[yɮIHir.;qVtzu%bd8+CI5HG1jqEa4jz5wP#+ ­  A<:q EO'ne lwwY[B "ݸ^ pSR]=9'ޙ>5ܯoxN*1:-K̒'Z<d) sܘī?h |Uu(lsM"J2ǭe^k\f9:E:dWbge(FIN;W89=v"D)$'J8\ԓMrz?٦[r¤ מI{UͦWۮ渳thmd9+Aּ[u;m <#2E3]TTS8ZTMr؉KUHfÐ$6K ZDʮr藑ǽ8T&,鱘Ze@nCw2}%&HHye0?QFNIP"Ah ޵2[O@(()h ( (PEPR@ EP0Z@%R0(ZJ@@Š)h)h KސR1E8u1ҥIօ|zn5iq+iܳoQBIVŵBkZ2Dxq^[S$$ss!jAކj3ҥ[%ڦ + OJZ&$^n&osز&hՔY=1 \*OOƢqX/!JTRJV^Sdyȩ@gPj;c4BEwD--=6񑚹;X^E+ݳ]%#rMJ䖗sIi!"M ΡyCkǮYeUrP`O@;WxO.LIגkK20*R}P΃L(LkɅU8QҩYN#.1Uuq,H;.z 9Tv,}y}ekj894ltҧ1pxZ~HRq~U*;)Ԃ.QV=Aqpj7Fx119vJޙΡ ESef:yB޽ O4V'il-k"+e3A(;cc*n,xBӣ=Ddҽ"9_SӥX EGRXʉgoֺh(MS,޾g}yzM.UNgM/BJ$ 9nuKsZv:ox'{xzぶBY2wXn RJK b:уX5xQlӵaSG4cRS6!4J?J榎6nIҝҔ(H OA,s㨭knI|\d`ώbOq:n+VLwe;9,FX!$d du&oy= EPdgBQeʣSӊӵI,PڭFfbѥ+]^kFʷ@Zk[g&"Ani̚}Nwlj|f,LZ"gi|bƜyz#RRcwױQ_T|8POE,p(K0P9&_ xpϵ 1ZѦiRu[3rJM `{WYV)g? (>]ް,!ԃQ`}wp="Z% :嫇t3I"92SIT (QEQEQE EPE-% Z(aEPEPE- IҝHh(PQRCE: JZ J(*xW&EɫGYFrͬy8*}+8 a h[];HARhZJ'#+ӂ@Ei[]2(²׊[ j99ү>y\I㒒34;K т1eFGX@㨯ZIi,rm`{bjƭPTPČ XU{5峇zZ~\=wͿՌ=kӕ'xifr. H?1Iz{-]hd30+Mw-VU.~UϹz Jc9Mp>iջ ƭ>ebec㛀Agioqi`^S|Jȹk{MC#nbI [2csvFȿX7p;fVA-q ,~k.8yue)JN[Av$  b `ד^xKVuKB"3;zڷGFmV|IqZb.x!EA]VNʍ ѓT[ZFI:aҘYOԈ/JH){Q_X~t!P~o7#=۴5 qWx4kܭ:JWMcEZ6&F>jJeGM+J ?J=b =In| HEI.>t{e`zk#T(Ts֢u)<=umSd'u]J2ïk]O*|i{?K :*.e,탞+aϵ]#ϓM`Ulj;v0iƚkC1((` (Z))iҊ;Q@ E-Q@Š(( ZCSHiz)JQ1IA'ڥ6HʸJPiMъv)@SP'ҢR`#޴m8C"LLi HDƄpO?J筗] &=3^}w=Z1EL=(nT&Dh;T iI-J=*K49$ۥHC+ĬM8ǝ ׎uu2/z Ix,8c8r+%{Go+|GsjZIidַE+=j(тJڭeMjo CPWZgke%85EjPB S8mXZX[2j1 +]X %-ےD HWe·՝$\U,DŽ- &М>zK_>@;O9T,Ɵ}Qɂ]ZĐ0G?uƼO!E9D.ot~ya,LX ~ vRMA&^G[;J-La!4bӀȠ ԨҚJ!ϵ&9a'ɡ^ u$֏?t9<&&a1aЎj)IDZrF͜E_@ӠcOQT'5h:tsӚUfg%)gg9{Pd $8uVe99 "Ss!T{ڹi8^-9'&9b' Y@H,iQ]_Ltlc}G`c&I&tR_Lڹc?4M{l|.w B9֮ 􄸖YcʍLhLἋyW`K,jWٵp^HBL5/+-a?rG5^÷yIzhw=ԏyV22=\8i̅N1z ˎk&G/sV_AXSxw^Ua?.1꣚|2{Wj;QgC^}\*%=:[+ٞPHĺsaxO$3j>:T#ORM'~*0P™#5ڴΨkIJ#" MtCLێ)M#pة2dμۖ1|CīOه!v8_IӚeWN= KfÆ9"%R8*xzҴTҎy3&*:ڤr{S$fy 1I';c=yeC[+,2 w'; qU>^]*V.bY峼ok1OOJ{b19Z8z5DqUF\KA+F3Y"s+կ+)!MCUH+4k;xS(#wU;*qR-o&L($}-Vmr:7yq-W jgc9Jrךf8yW&\]xs\K"R#╤>ks6}u7!#/9aҾyFwkwwqw#leJ-Fu'Q͹׹xF2V^UM180=kšү ju!ds(N!o$m<9bY][%E9@x!+*AjKB..Ёӹ5` WMvz%4n*5Υ.}%Ės Г;ԏ/*7~k\ghȯ\L0q^+[aE7@ҽ٣mVX1k,55.&GCOk"$s օb&`yד;m̿ڔזk$x}?y]ga^8^.[sSPJ(Ti8TH NTBG=Q׭1N{SٲԀsMQgJh!|X yN>J@<=X+!N.Q=)Xkڗ}7c>a\浩ɩJz7s‹rhVu o W[kUNJM5J+m)f(ͫJ1\r\[B;97ĺX>)@FӥH4P>W|Wⵧ=w2µQsƯ'үZOzkJs21N;_ BR-߽t=k;KO.@Jӵ7#'=+ƪy%vxPAo|#0 u8=AR*tqqTtB SK4q~H#]c5 fa!yNjnռ51J ]xzՍ0Kc{\ܞFJ,hlrpZ?R|*KIJH@H_Z59Jև{c-M:޼ڂY],y+'i83fu%F >LzC]R_c/{wNBJ:=+:DjR;vAZ~!v[t[p<A#Rit9=<֦rǩVlZԮ`]@E$M&bwe5wr"(@F]c^6Nkm(Ӟ3%5k{5/i> E@Y~&՛U41!BG.[ԁ\Y|ѩ+^<ɔԧ UoIA7y2vl* LυA3D9uZX \a41# Ђ=)Q5fTe>GKM=sK1ZMJ]XOAXtD>oVrjWAjRl/_Ux#Ao2@죩~bC"Fos԰h#gg,1*rdr$޴*m ֿj56K+ٛrLgcq! }=+'wЗVRHű҅&HZ 1~5$\ Ez<)V|{E%9AJ)(RRIGҀIEJ(@ (QEQ ZJZ@RU7Lme9(.NȦk߇Uf\*/mD_&rH@O-1Wh3a$F#=*yx$Q0E\!@5G6P8*e]1֭TLs[1C4˽*{-BK{XH0k/jm#yS|Os<ו|{ ׾ \Aq`@IYr7~#aBΥE5W5\ʸs/CfC8枼uԠsC- "sN~SRht5J2cRտkX{UxnS*͊WFud}K#-qVcF|`>NqOH"n pkr8޺[ݭΠyX#h=w<+ZIuPOz hN?crµ>r g&\J#m$ 퓲X`U6) nr*@jdp,q.Z`OThe1W&KEaKwao:GUw'?zR^>:ӵŻsZkuɎ۶y`.kY K }+HLtc.j u3pjI߂8(傫`dt6LPEhfa }qZI'+:0s~<9F6c90RCYGS 뚊NU5CinA* QZhSl[i|?zGF;UUI+"[k 6*HEiI(*Twe295/zԋksbOά$$Gnx\:WS?/vI|qW%e'a sYJQLz윞Mw:@H乁'yhۻ#ZQh-#u#uYFJױHDpP{U;LC$ˌփI 1ֆ#GaR$:iЬzTF[֪e)&0Á\1m 8PWV9=)ڥk\3p%пgf6&,dQe֢ZOe$]fAnz/dxNVXċ)Y ^Y!BO #EOޱhxY=vG{H_PT.x@9{0'UVGB }1[zUakd;(@N|^60Phq(`QE-%P!i(E ( ;QE (J\A9^{829 7#?#>ƱEV+f+:Rsgcfzlx %3ܺsyHAɮw:W_ =,.%JMuNֽb{Y3\8=PnG*ծDjevG&OZN<ʖ8_h!lA!$^*bj);"6M5&3Rk4v Hob(_}:Z@>YRSO`pkr )SӼt%=QpROaw}4ok:4O}gֱՂZP±|O, # NkKLIJg'ZQKZi:\T\޽<9n5m u}+N+S@_2#,s2[w`Pk5 B0~ &\":UCڠWhgmȯK;pq\=oD]5bC3\e\wJ0<^e̷p3,2Kkiͤ\>VSҼ$Ӂw!C+TjWcSG6/w3OrkMZ;4XQި: G$T;bS6w ňIRǒOK#Q*WSaiwPGUݖ `%Ie%ך!5=>/08ߌ`٦V.Jݬ`xKYu2֖khT2+VJ|<\;%bOjiqw`pUZ>XtzUƮZbĠ|̿2ЃזI%ܓM#I$f9$W.n YTzTDTN 2dR7}Y &a.ͤ"Sozf2a.ֺCK8',9GLg=ɫ]ťsiNI94W  pȣ%?Nx9؇UP@\PUK:Fp1&M{o.d`NqQ\N}k>"n#5_]ԯ79tlT0'k4ԵE&n:natX޵\K‹x%@#3&cZ:^"Gujkbc88IԴ)Ԭ/:Mm(9*^&pSKC}oaX<cp{My6:oǚ;`7QX,#'=sZ:jPwZ(ETõ[“S]htVey$xy}.%P?J֎DێEsKFu*h֗q "5K2YI>2F0gXIX-O袌Wޟ\R RIL( %u(((4PKIE1 ;RR1sS[\Inb4kToA+\ ukR0N{yfɞB$OzD0j,,٩SiJl)9r𷞫=S]kn#F=XHżJ*ʹAq_?_);ݣUd>p)YƐqd;z衳T=AKՖFpEaO:Te>+4=]h֖F$1WQ.~,OSYHjRT87bH.t9n"bK\lU'*^׶Md(pr+Eq+˝$繯ZYUzuH*u}irB/ IC O $NFjQl5I4=hѱo8tG &b{YHO s_0J>c^'[-8X~%~M{''iF"H4*/$&pzqsW!AsGm8FYryFf5sɝ^T=鱯*`ֱlEOU>Ҩպ6כsךAg+rF:V:yש^{,8=ǽy-fNzbctV =[E/C h +~Eݫb89V<;E/GEaG! RnM3G*|cK,oUU{7Ȥ2O2lWo$zq֔!zT!zTX[_%T|9Mvp:χ46M/˜bSrͯ YƖ>c+GT Thk*"# AN¼V3hrn\ɔV/-ދhдCl-wW̅S\7chxi@SkO:$VuqpN*+Uz,I7Zuűı2jT-T4-?UFG;Cyr΅]y!zt5ɺ`WNj+ͩIِR{ SHLZ(QP:R%-.Ӛ1Z1E1 KGI@ KIE0RQ@ E%.i$-L@roOkK*sYV<MOi8(r-k)=k z:0:f9S_1ZNJ5F3qRGp%n:b)fwåY2cI슩%5.7l*uq^+yK潂VRڬmMٹAz&gCc޹ qkƝ٩of<{Mzl:mzBrk杏.oS "m۸nO܅gtӲf\ٸT (Y<zHp9<+>{ #YK{<"Y `OҺZT_]FՐH=+[@c9#=$.f=f; +.. DGqq7}M'ks,֪ٙ7u.VR#Iag=ku4m.y+i%E$zFk׆]DBbwQs)h$`MnwE N#5gQ[yyy{knTa/"< 2GSmbN3*).i3RFXZi$JK7j,tx6уVMkp(^+X!t97H)uȮ RD`6M1+\a*{4MyM@ ǾE)8nHֲsl rdM0JV!c,N?JI\CX@PhʄT2rMY&"(?Zӑ4ӳqҘA;jo%bO9eA8-lSN%Y $̪X.N|V\Ӥ10j妱./m ”A=OS纗tH:We:P); ~ӒLWonM;LP2:;v)+MMk`9N&Mϡ0)`4do8t/YiAh۰@8'WFޟi$ ^JzI󳃍 u9J\ xX|jaCR=FkG!ҚJdEGb |Q$QxB 5 fJŽj@XW[x. W_xFL!;޺p 3N=}'c\K`{W78m RGރֹW5 0GcPxk:l6 ZM0}= Y@jϘ' ֦L@iE'J1 G֒.y ޔSih/iRʟN;5 qlwp>J#zu 7F@s3\]n죠m֍֢=b&sVlJMoc&E 3֥A"1%24*)ڰp~v$JlQոg#8VQ (QyHHJӕ=J.;M _OQLqNU銕SKf zM=W]Sl+BvuAN8ҋk]&O:t&dO8>­[KpU"yG{Hʹy$KaM %lXk*Ƞِ\J䫈9jb.6upTj0™M'@{TQsus QDkd(+f]Q=yh>#Vqu&s]s>i2 ٠&g.83Q[ܾW*Z|ܐ--̛I8 dO|v~Cu|C#-EW/n`q%s1kdɩy,v{8Y"BX:Qɻ`c#:wQg)5RZuyZҔ;#uDe+9uYʖi~o-[g3Nʇf{駇4Nvd.;W#x,/֧.ƥi0h%Ad.u63g˄aG]PB 攡i֝͟ +)NI&ME #OYlsU!QX|;'NհQc"B R:TZzޯEmWy$5,!TrI[|SVIrk̷9Fm5u#l,xa\HwkSU̕°cEQI| DNI_JJӧ@=kҴ1.=]\tZ$zb[c#|Xzo4ĒֳM;K;Oj͚<6Q iiRS$8@Z\,xm#P8yyފ[ܪ@_?Mٞ)Afic8CdG A5n;wOv+\AlE. хNFqLI KXZyB/aNJǟ|V; )1]?O Mʜ59ɯƚLL0iM4YHii(<@ EEJ)---%:RR  \P=G5-*KGҮұN7$?QWڒ{gIiSQfDn8)ЀďTȧ~*.1d3שyԊT6h=,qՄCe"%LԫHH:sSEr E T\ oTĹXH9>ߕmX4HuR!Պve\$,ZSD)+e'# RmfG2X  2϶}*Hs'cza-n9$e[BU3J= *܃\ժ;R|t!\8ZBr{z}8҆_ݱGZ4[~4ZvI啽݋+s)܋z-p88WZHͳgZɛP@$J4%fvN@TZi`R d5֫ҧn+I%-)%檞'vʧA'vXN?7z<%m<"]x䎕KpQz$t6,3׭s֥5ciJ !+8KeEvW:6` ezC*%q*yURpmmx] EU<;٫>T/snat CfqzrZJE@2x{ˑ/ESk\1sJk' k2qW9Ԏ(% ')ӜGma<[ b\h][ⶈ;O]tmnD*Rw{[2 FGCYrX]Q8m-}I"A44I54޴<{SQ@PhJ`jZij9;{uId5ZOm*FC\x$kx|S1 J?xLkL !}zo{VtgeMJ>=kG} &tɢ`L*a6SB6dgҩ7qڳY)2Tn˒D1q)1JZX3ۂ5J +"vEqW!e݌l.`̏:֎H$E'8'5rd9P:V;{X|kʵwGԮZY"vhZ^[D2"]fkmou( jL,AP.ľihpW:+jb;d_5 6=뫷(Wiᇭa O:Nh4IJ͏ޠB<}r+(F@VM0j\[( c#8 .S>oynhVXHK~&qXZ+2!Lǯ8D[y.v0ajo6Ղ#ȓ$qSJQ䔜q;9:MFX(^N7HT}Msz%%q,y~ivRNSJ+nAk/O2F@5r],.T}aa+k602yi *|-،q7D^<7O^Fγ+5brx6[zUY&={WTitƚEn⫴t%{7bhbI9f=늴|qN!32񊍥8%y3IpWr*1ibLnj0:3@'J@JO 6M-n{Һ 3Y 4~[~eVfCoYx"ˤcc MN2er"Ycxy9w6eH2jVhBGlG(AZox aNJiǠBOQP&c[Gb!j첬:[ErjVRdEF8EtWK)&6T#Z1W&`ln+ǃZQKmr} VԞS}(rwDKv"fK'$9M{Q NqZج ,{=ps qwrg#5Rͨ2ǚ_Ң9AEУ;H=R'2 lpDZOʼnC~&yc}n5Lm2,e=Y[U sՎ2+)syJ,em+LFr>r <זٓ !+3Q! 8ϵj-wi4E7;`gkJQqSJn롷q 浣P'8\%yޠ RC_ujZ~V{{{I,\=ěI=ц˹.7 >n+Av͞8ɨc'8is>>QLLRb (P0(K@R (.(bv(b::ю)q%-@SD*I+Ѽ~툔U*ƚ:ršP+fo|#/b]OEf1]}ueBqWhUm"|-68 \oYh}Zi l՝D^~`i2`C|SJs޺4])<$I>W_f% *m&U;Dkq.zהwRp׬X]EwȄfU7{T\}ۆ* ,1,"m:⸛͐Oe 39TW;jXjq;._nAݧθG3\ #)jrIxi{Ec \SNRۖ#5x|6r hE+4aC{V0VҫF &5 [U=`HM\})m\a*h֬GQ:zRL"vQj%*1ӥ4R/kA68VJlpsvGXG?qfq^dwtB&!A\:΄uAb3Uh2@Mظ1XҴ H\[t#au;RGK;`9-WĬĸ`}kķ.5_Ķsi1C2 >ҹlcB1ǥN7rkF%$ixd5,h82;O*F&u: PRjr6nKPs.xpя46Hk4ǐOxfZ|uW<4vs W(]XgO6=3S6vЋt^%ԑxn _%q!:)Lk_!|b9vZ^<ĹK CX; ~5as"e''ިiTdk-F7gh&͟ ,-ycXLrjxn?}{4ao#Þ!q'5*%Q3MºFeMqsڸk/+<+CV&ѣ嚥EVuc9u>yv6]Iqy,+'vӋy[.PQsRƼhy *f{Wa6ڠb+叕5rbdu2҉ywca;`9ǡ"Қ{ϴiq'5v۵c9H˝jβLw_s(kT`9i].m!P&-wh*ZGnW{ ˳tkKbM, ΄_2ܕRi^;ȱ#ڶWJӬs\ZƸֵ8Ybg1+$*H]1ɪ1vʚ e$bmwbdVaVAo!JҩK.7pޒ;3HX[ih\7!Al+EVEdBɆB$#B=Er]ݟ0 c^Rxb?fiWr]I#ҽ 9۩NaSּ%i! vYmy ҸZKw_\Aj-YYmO|ѳ$aR9d3D+Z*g 7Q~(RW؟"%h(GGj`%( KE(@%`X{(ԖjMKڤJ x%5Cz溆`:cN2=`$ 4+|Uao\XT sDcr0è8WVʤQvS p %ooLҮB8z",Gq ^Հۈۺ|>uZ{*k2Քq]$4)$xHVk@mľ]ؑ`CyO:hxZp<։+u̹Q[&Wou- \W2F:W DjF*+:/kFVF; :h/ OQx#ZuLzW[=a!bH55R$@SM35]ϛu{KVcOzLkou 1Up;VV0XDQwRuck-NU96"G p:Wh(X)UXIT'ҹvZVC4hm#T f>-''҄5+HPׂYM}k:| FrI2HJ:y 9*kۅ{GGe_z%'tik.K{v2a?rK8Z(}{WGtT;G>ͺ[1W_j]Y=3Q؃upGV5[ɛ&S#th)-Բ2/ lgryREm 8VA5ņnT>R%>^&ܗ/sIw0gh,o "|7CYqGB!r0i&ILjFSIXt76ƣuy,0ҶDH0)[jR$d*Wne簮V#5kV5 bEf#k$dvk=LWZT-aQ4N-ziyiPFxe ;e酉=iƹ=:ix[K^HUWRE)Sk bܻBE qN<,8ϖkc@n1F'z|\-9c1`A)AEYJ+B'lo#>աD֭B VOj, 4!nktU!¼4k-n_C\80M-GBQnwF$2i鲫+gNܒ (cJ҂ <ƴݣ9=mMD튢@f<ߍqkk&Y=#KH+yv'{Slܛ{^a8dakWi&SFFRH s<ꚃ=nf9$5j~FiURzjkl/ r]Ob+ypqO޶ewv7qGo=!1eҨs*3x=*Z/!8Sڮ-7!l廞'[6ԹZ|(4I#D94P!(K(3֊S(GbPE.(a=-'zZJ(Gw?Ÿ2䓁\(Fi{R"95ɍmR|^ S~Th08f!:=_-+(Ƈo!ա{ͪIC)^_PJ,mbӠ{yVP|<ֵe5KN.͞zJ;ӕrk#XEt 3_߂x\pM*|5N6NHI[qqlC)Wcmy1&'@cV\GF͜l؂zmvUV-#R΋N_N;:aKP \FᛝOQO3nb.Oio c$Lax&qJ(9dNJAot V9jKc` ҔE9b5 }F4r5221r{[oR(d9\TځbF* ]xve`5 6[vf;3o*H젒@5'l{ȸ,6'=iDkB[枱CI?ZW.w>^F8lfhMBcޱƾ w.x5=ܻ7Lk{.45=jI s'Iu&;sV[F*:"F'pqPF簫e& |uш=xpM7QˁګxX+F6#y\}a4+?,ǟZXhs:J09'51` q޼q. YHVS.)>kboYCpWkr&:V,Oj۹75фQ+ ^Esj{x2MGWW1HRj*\O =Xuk (j5 SMqgy3+ͩ>wt{ ։1!HC\'ǒP]UpTGbMzPi~)I'\ïi@+ n2 =w)h##pGT*:M>[yHףұpb͟Y8AN|ݪ/K 4m?STy|4UtDv3Ak3/$U8 = Zm NU=#P^-+gS>I5Q}u**TU ]^ӭqt:q+ ELʮ6Dbxz=B;k規η"ֹ]1݀IЫծ!ABOS.Y{XbIcbfA3o?qĎv@+ƽ-YSQ*aR%YdzuWUP%<8s JDzi ||wWB%1Ökb `uIe:ڔZ^S[Y^#my4k #u&{b+yĩpc4n'-E p4'*zE Wz8 `q޸^{BHRHkV0 WiF@9j?/NIu_IL;^ jNwL[Y;I^P F {V$s XJA]藆yfh*Ir6_4exmhh GO^[H5rkt),'E2 X+mނE ]TjT ӿqa#d1å˱rIj|'5kd{[?IڝLs}Q#M%8P!)1֜i1LBKOƁ/j(aV6S^J,OKi+۲+`K ҆#*}CE +i'kqUj:bpS܎yY"PqT $60 W,PNIZJ#񬨥dTгW%)7!$Ny ֨_W^9y-< t0u+kZ1+yUGuң {׎+h.UsCWp?oa'4ƀP=kʝg9\jϟSjlhq;?M=Sźro!LT1f #Z[j9S;AlRKn bW#㋭"{EܮFs;^ԥHrnd,NMmF6Hڕ~)sҐyNlζAF vi+>Nf]΅b=V45lH23uQZ/mps֧ԛ% `g#T~K854ŽxWO/b,@=WD L:U+ojD8;^zG+ 6q\i%8xW3T 1P:rO{ٰFNFkIͼ;q]ll˓É[:-iڬ>EM p.q#5p&ŵ}$ jN42X))(j]-޺xדt+t>VáJZ:>\:xyPkt?i>YGz_63WSQ;%s׆6 nwPvҩk>1.#wl:p ڡҸnY&s;1{ZuwȪzt[uy@;ׇu} #HIk9e41xt>!MTc^)'BZ5 j i.O*ӃSpL#QYVq z\½YRZTQ :o3Z+y\cѣ^@gDeA.{V|kQwE"ڳd Ҙ8ׯ"hxP8jTS3\ӦD"{eye`*Ճ!8|Ikuer\בȬ]'M=b5F[|=t֗+N}+"ɮV[vUeZIE'es-!Bb[ ؠ/^*eR:qQZHJyDynhė˛bpܑuZˋIY]X'U t2J빈-ֳu;^mpy(@w1l`ןJTQ[ȦjyuwfH>lWWh7V]MM; 3:+ǚzJJJg⦇54#5Le9\֍r:B9;`N;`hٴEjagkNt>njp9J5iYh@4kG1,x瞢`sq֐D'!B V̾51ޒf8j_+=: Nk݂t2q:vdx6#E Pp{jv64p2?6OL7Vf+haau=ֆ[i8MWbMU(4QL %S[Ó5(N+KҔ( 袼l*ɞOa4r`zYnYBMWiIOd(s/dVVۀaȢQI*ĵ;y[5DE}4RKCm!94( 2i QL(&)њ(bFh;E4f(9MH(eij hKW=DvQlԷ_(f^e۠TEs HjFO֊*Y*r}KК(v}N(ɤEV!r\ܥ8WvA]ͻq*|Vp9cEfE%2L~"{_l&Y"g&0 cxKcUu= Tb`=G[YnT=v4Ca!p9Ѽ9;z 0mEai̵/&WSQMW=hPYu{xQExdw<6۹j4a\Qf#fpsE)݊84ԗg iѫ[!}yjL*P< ]hFD ާ&@|c)WLd:%qHa*k=b B@( d&E9^%W k+\5Gk#0)jv}AEnIR{zS[i&<8v:}RO(&;18OĒ0. `W1EEͩF)"JhVQXl44kqUBtEx~3Ub3SFbz(a%a(,)y1RB8#Qi=r؞ t=jl-u=MW%: ^7w5@;2'RY=h[6"8$`pċ#۹Aמ+7->]x{4obSEVV;k
Warning: fopen(https://newsweekme.com/wp-content/uploads/2016/05/2016-05-27T141838Z_845274940_TM3EC5R0SAI01_RTRMADP_3_HEALTH-SUPERBUG-780x439.jpg): failed to open stream: HTTP wrapper does not support writeable connections in /home/newsweekme/public_html/wp-includes/class-wp-image-editor.php on line 428

Colonies of E. coli bacteria grown on a Hektoen enteric (HE) agar plate are seen in a microscopic image courtesy of the U.S. Centers for Disease Control (CDC). U.S. health officials on May 26, 2016 reported the first case in the country of a patient with E. coli bacteria carrying the mcr-1 gene, an infection resistant to all known antibiotics. CDC/Handout via REUTERS

By Bill Berkrot

NEW YORK, May 29 – Drugmakers are renewing efforts to develop medicines to fight emerging antibiotic-resistant bacteria, but creating new classes of drugs on the scale needed is unlikely to happen without new financial incentives to make the effort worth the investment, companies and industry experts said.

American military researchers on Thursday announced the first U.S. case of a patient with an infection found to be resistant to the antibiotic colistin, the drug often held in reserve for when all else fails.

That put a spotlight on the urgent need for new medicines that can combat what health officials have called “nightmare bacteria.”

Drugmakers on Friday acknowledged that in the absence of a new way of compensating them, it simply does not make economic sense to pour serious resources into work on new antibiotics.

“The return on investment based on the current commercial model is not really commensurate with the amount of effort you have to put into it,” said David Payne, who heads GlaxoSmithKline PLC’s antibiotics drug group.

Other pharmaceutical companies expressed a similar sentiment.

In January, some 80 drugmakers and diagnostics companies, including Pfizer Inc, Merck & Co, Johnson & Johnson and Glaxo, signed a declaration calling for cooperation among governments and companies to create incentives to revitalize research and development of new antibiotics.

It proposed a new business model in which profit would not be linked to higher sales. For example, governments and health organizations could offer lump-sum rewards for development of a successful new antibiotic. A British government panel suggested this month that drug companies be offered up to $1.5 billion for successful development of a new antibiotic.

In the United States alone, antibiotic-resistant bacteria causes 2 million serious infections and 23,000 deaths annually, according to U.S. health officials.

Unrestrained overuse of current antibiotics by doctors and hospitals, often when they are not needed, and widespread antibiotic use in food livestock have contributed to the evolution of antibiotic-resistant bacteria.

But in recent years, major drugmakers have poured most of their research dollars into highly profitable medicines to fight cancer, rare diseases and hepatitis C. These drugs not only command high prices, they also are typically used far longer than antibiotics.

And the companies, which have come under intense criticism in recent months for continually raising prices on popular drugs, say it costs about as much to develop a new antibiotic as it does to bring to market new cancer drugs that can command more than $100,000 a year per patient.

“Drug companies can’t make an economic case for investing in superbug drugs,” said Erik Gordon, a professor at the University of Michigan’s Ross School of Business.

Gordon said governments and foundations need to get more involved in research and funding to spearhead efforts to combat the problem.

To critics who argue that U.S. companies have enormous cash reserves that could be used to address a public health crisis, drugmakers say they have a fiduciary duty to shareholders to maximize profits.

ON THE R&D FRONT LINES

One reason companies are calling for alternative compensation is that aggressive sales and use of new antibiotics could help create ever more dangerous bacteria that develop resistance to the new medicines.

Glaxo and Merck are among the large pharmaceutical companies developing new antibiotics they hope can beat back resistant bugs, while Pfizer is working on vaccines aimed at reducing the need for their use.

Industry experts said small, lesser-known companies with promising approaches to tackling resistant superbugs included: Entasis Therapeutics, an AstraZeneca PLC spinoff, Tetraphase Pharmaceuticals Inc ; and Achaogen Inc.

“We believe plazomicin, our lead drug in late-stage development, has the potential to play an important role in treating this dreaded superbug,” Achaogen Chief Executive Kenneth Hillan said.

Allan Coukell, an antibiotics expert at the Pew Charitable Trusts nonprofit research and policy organization, said what is needed is a wave of new drugs based on new chemistry or that work in new ways.

“Most of what’s being developed are variations on drugs that we’ve had for decades,” Coukell said.

Pew has outlined what its calls a scientific roadmap to create a body of work around new drug discovery that companies and academic researchers could draw upon to help jumpstart the process of finding new antibiotics.

Glaxo said its experimental antibiotic gepotidacin, in midstage testing, belongs to an entirely new class of antibacterials.

“Based on that, we’re predicting it would work against infections that could be caused by bacteria that are resistant to available antibiotics,” Payne said.

Other companies with late-stage studies underway for antibiotics include: Cempra Inc, whose drug was recently validated in a Japanese trial; Medicines Co ; and Paratek Pharmaceuticals Inc. J&J is also putting money into battling antibiotic resistance.

“If there is a bright side, it is that the world policymakers and health leaders have focused on this issue like never before,” Coukell said. “But we’ve got a long way to go.”

Social Streams

Comments

comments

Facebook Comments

Post a comment